Atlas Trials

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Clinical trial NCT04449549 · RECRUITING

Trial details

NCT number
NCT04449549
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Neoplasms
Start date
2020-08-24
Primary completion
2027-04-02
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.